title: Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma.
abstract: BACKGROUND
  The prognostic value of serum ferritin level in patients with peripheral T-cell lymphoma (PTCL) remains unknown.
  
  
  METHODS
  We retrospectively analyzed clinical data from 78 consecutive patients with newly diagnosed PTCL that were treated with anthracycline-containing regimens between 1998 and 2011.
  
  
  RESULTS
  The patients consisted of 50 males and 28 females with a median age of 64 years (range, 16-83 years). The subtypes of PTCL were 39 PTCL, not otherwise specified and 39 angioimmunoblastic T-cell lymphoma (AITL). The median observation period for the surviving patients was 50 months. The overall survival (OS) was poorer in patients with serum ferritin level above the upper normal limit (n = 28), compared with patients with serum ferritin level within normal range (n = 50; 4-year OS: 23% vs. 72%; P < 0.001). In the multivariate analysis, poor performance status (P = 0.006) and elevated serum ferritin level (P = 0.018) were independent risk factors for poor OS.
  
  
  CONCLUSIONS
  Serum ferritin level is a useful prognostic marker for PTCL.
authors.affiliation: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Koyama
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Fujisawa
authors.affiliation: Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Watanabe
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Itabashi
authors.affiliation: Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan.
authors.forename: D
authors.initials: D
authors.lastname: Ishibashi
authors.affiliation: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ishii
authors.affiliation: Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hattori
authors.affiliation: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Nakajima
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Motohashi
authors.affiliation: Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Takasaki
authors.affiliation: Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Kawasaki
authors.affiliation: Department of Hematology, Yamato Municipal Hospital, Yamato, Japan.
authors.forename: C
authors.initials: C
authors.lastname: Hashimoto
authors.affiliation: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Yamazaki
authors.affiliation: Department of Hematology, Yamato Municipal Hospital, Yamato, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Koharazawa
authors.affiliation: Department of Internal Medicine, Yokohama Ekisaikai Hospital, Yokohama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Takemura
authors.affiliation: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Tomita
authors.affiliation: Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Sakai
authors.affiliation: Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Motomura
authors.affiliation: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nakajima
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005293:Ferritins / Q000097:blood*; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood* / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018943:Anthracyclines; D005293:Ferritins
keywords: Peripheral T-cell lymphoma; ferritin; overall survival; prognostic marker